The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety results of a first-in-class PD-1/IL-2a-bias bispecific antibody fusion protein IBI363 in patients (pts) with immunotherapy-treated, advanced acral and mucosal melanoma.
 
Bin Lian
No Relationships to Disclose
 
Yu Chen
No Relationships to Disclose
 
Hui Wang
No Relationships to Disclose
 
Weizhen Zhang
No Relationships to Disclose
 
Xiaoshi Zhang
No Relationships to Disclose
 
Meiyu Fang
No Relationships to Disclose
 
Yuping Sun
Honoraria - AstraZeneca; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - Pfizer; Roche
 
Di Wu
No Relationships to Disclose
 
Jiuwei Cui
No Relationships to Disclose
 
Xinjun Liang
No Relationships to Disclose
 
Ke Li
No Relationships to Disclose
 
Huijing Feng
No Relationships to Disclose
 
Qian Chu
No Relationships to Disclose
 
Xingxiang Pu
No Relationships to Disclose
 
Yueyin Pan
No Relationships to Disclose
 
Meixing Sun
No Relationships to Disclose
 
Maggie Zhou
No Relationships to Disclose
 
Yuling Chen
No Relationships to Disclose
 
Hongli Wang
No Relationships to Disclose
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere